To the Editor: Dr Kesselheim and colleagues1 evaluated the clinical equivalence of generic and brand-name drugs used in cardiovascular disease. I agree in general with their statement that “ . . . the best evidence for clinical equivalence emerged from high-quality prospective RCTs in patients with cardiovascular disease involving β-blockers, calcium channel blockers, and statins.” However, I would not lump the 3 chemical classes of calcium channel antagonists together.
Zema MJ. Equivalence of Generic and Brand-Name Drugs for Cardiovascular Disease. JAMA. 2009;301(16):1654-1656. doi:10.1001/jama.2009.521